BridgeBio Pharma Total Current Liabilities 2018-2024 | BBIO
BridgeBio Pharma total current liabilities from 2018 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
- BridgeBio Pharma total current liabilities for the quarter ending June 30, 2024 were $0.134B, a 22.02% increase year-over-year.
- BridgeBio Pharma total current liabilities for 2023 were $0.144B, a 18.46% increase from 2022.
- BridgeBio Pharma total current liabilities for 2022 were $0.121B, a 10.1% decline from 2021.
- BridgeBio Pharma total current liabilities for 2021 were $0.135B, a 41.21% increase from 2020.
BridgeBio Pharma Annual Total Current Liabilities
(Millions of US $) |
| 2023 |
$144 |
| 2022 |
$121 |
| 2021 |
$135 |
| 2020 |
$96 |
| 2019 |
$60 |
| 2018 |
$33 |
| 2017 |
$ |
BridgeBio Pharma Quarterly Total Current Liabilities
(Millions of US $) |
| 2024-06-30 |
$134 |
| 2024-03-31 |
$141 |
| 2023-12-31 |
$144 |
| 2023-09-30 |
$106 |
| 2023-06-30 |
$110 |
| 2023-03-31 |
$97 |
| 2022-12-31 |
$121 |
| 2022-09-30 |
$119 |
| 2022-06-30 |
$141 |
| 2022-03-31 |
$103 |
| 2021-12-31 |
$135 |
| 2021-09-30 |
$96 |
| 2021-06-30 |
$132 |
| 2021-03-31 |
$95 |
| 2020-12-31 |
$96 |
| 2020-09-30 |
$76 |
| 2020-06-30 |
$93 |
| 2020-03-31 |
$65 |
| 2019-12-31 |
$60 |
| 2019-09-30 |
$40 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$5.045B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
